Vimian Group AB (SE:VIMIAN)
:VIMIAN
Want to see SE:VIMIAN full AI Analyst Report?
Top Page
Vimian Group AB
(VIMIAN)
Select Model
Select Model
Rating:69Neutral
Price Target:
kr33.00
▲(22.68% Upside)
Action:Reiterated
Date:05/01/26
Overall score is driven primarily by strong financial performance (improving profitability, solid balance sheet, and strong free cash flow). Technicals add support with an upward trend and positive MACD, while the high P/E meaningfully offsets the score due to elevated valuation expectations.
Positive Factors
Strong free cash flow
Consistently strong operating and free cash flow provides durable internal funding for capex, acquisitions, and deleveraging. FCF exceeding net income indicates earnings quality and reduces dependence on external finance, supporting strategic flexibility over the next 2–6 months and beyond.
Negative Factors
Gross margin erosion
A material step-down in gross margin versus recent annual levels suggests structural pressures such as adverse mix, pricing pressure, or higher input costs. If persistent, this reduces operating leverage and compresses long-term profitability and free cash flow generation potential.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow
Consistently strong operating and free cash flow provides durable internal funding for capex, acquisitions, and deleveraging. FCF exceeding net income indicates earnings quality and reduces dependence on external finance, supporting strategic flexibility over the next 2–6 months and beyond.
Read all positive factors
Vimian Group AB (VIMIAN) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr15.67B
Dividend YieldN/A
Average Volume (3M)772.80K
Price to Earnings (P/E)39.7
Beta (1Y)0.72
Revenue Growth6.11%
EPS Growth79.07%
CountrySE
Employees1,200
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.07
Shares Outstanding525,964,540
10 Day Avg. Volume366,844
30 Day Avg. Volume772,803
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)2.10
Price to Sales (P/S)3.45
P/FCF Ratio16.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr30.50Price Target Upside13.38% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)0.11
Revenue Forecast (FY)kr470.74M
Vimian Group AB Business Overview & Revenue Model
Company Description
Vimian Group AB (publ) operates as a global enterprise in the animal health sector, segmenting its business into Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. Through its Nextmune brand, the company delivers a comprehensive port...
How the Company Makes Money
Vimian makes money primarily by selling veterinary health products and services to professional customers (e.g., veterinary clinics and animal hospitals). Its revenue model is largely business-to-business and is driven by (1) product sales of vete...
Vimian Group AB Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 431.11M | 425.00M | 374.80M | 331.73M | 281.31M | 173.35M |
| Gross Profit | 239.92M | 292.80M | 258.30M | 229.43M | 193.99M | 122.85M |
| EBITDA | 112.00M | 104.70M | 82.80M | 69.19M | 39.20M | 36.16M |
| Net Income | 36.59M | 31.30M | 18.50M | 9.84M | -7.20M | 6.59M |
Balance Sheet | ||||||
| Total Assets | 1.16B | 1.11B | 1.11B | 973.68M | 923.56M | 640.72M |
| Cash, Cash Equivalents and Short-Term Investments | 50.62M | 55.00M | 64.80M | 37.50M | 42.19M | 55.11M |
| Total Debt | 248.87M | 238.70M | 233.60M | 313.80M | 220.96M | 180.37M |
| Total Liabilities | 428.44M | 401.00M | 403.30M | 446.97M | 442.06M | 282.08M |
| Stockholders Equity | 722.51M | 698.90M | 699.90M | 526.37M | 481.81M | 357.41M |
Cash Flow | ||||||
| Free Cash Flow | 97.08M | 90.60M | 43.90M | -43.48M | 15.01M | 4.52M |
| Operating Cash Flow | 111.21M | 105.70M | 58.10M | -28.58M | 25.31M | 16.01M |
| Investing Cash Flow | -133.58M | -112.80M | -76.00M | -77.68M | -188.53M | -115.00M |
| Financing Cash Flow | 12.43M | -1.20M | 44.80M | 100.55M | 150.23M | 123.94M |
Vimian Group AB Technical Analysis
Positive
26.90
Price Trends
29.41
Positive
27.99
Positive
29.06
Positive
Market Momentum
-0.08
Negative
61.64
Neutral
94.84
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VIMIAN, the sentiment is Positive. The current price of 26.9 is below the 20-day moving average (MA) of 28.66, below the 50-day MA of 29.41, and below the 200-day MA of 29.06, indicating a bullish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 61.64 is Neutral, neither overbought nor oversold. The STOCH value of 94.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:VIMIAN.
Vimian Group AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | kr15.67B | 39.71 | 4.54% | ― | 6.11% | 79.07% | |
69 Neutral | kr7.50B | 33.16 | 15.16% | ― | 18.06% | 10.57% | |
58 Neutral | kr13.03B | -2.59 | 3.34% | 0.80% | -5.68% | -1106.19% | |
58 Neutral | kr12.89B | 17.37 | 14.22% | 2.48% | -3.19% | 9.21% | |
57 Neutral | kr19.16B | 34.50 | 7.24% | 0.46% | -0.32% | 83.82% | |
53 Neutral | kr19.89B | -38.73 | 3.08% | 4.25% | -7.22% | -317.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SE:VIMIAN
Vimian Group AB
30.00
-10.30
-25.56%
SE:EKTA.B
Elekta AB
52.40
6.84
15.03%
SE:VITR
Vitrolife AB
95.75
-45.60
-32.26%
SE:ALIF.B
AddLife AB
160.80
-35.76
-18.19%
SE:NOLA.B
Nolato AB
48.95
-6.85
-12.27%
SE:MCAP
MedCap AB
497.40
80.40
19.28%
Vimian Group AB Corporate Events
Vimian AGM Backs Capital Flexibility and New Long-Term Incentive Plan
Apr 29, 2026
Vimian Group AB’s Annual General Meeting approved the 2025 financial statements, discharged the board and CEOs from liability, and decided that no dividend will be paid, with profits carried forward. Shareholders re-elected the existing five...
Vimian Starts 2026 with Strong Growth, Higher Profits and Management Changes
Apr 29, 2026
Vimian Group reported a solid start to 2026, with first-quarter revenue rising 8 per cent to EUR 116.0 million, driven by 9 per cent organic growth and contributions from acquisitions, partly offset by negative currency effects. Profitability impr...
Vimian schedules Q1 2026 interim report release and investor audiocast
Apr 21, 2026
Vimian Group AB has announced that it will publish its interim report for the first quarter of 2026 on 29 April at 07:45 CET, followed by an audiocast for investors, analysts and media at 09:00 CET. CEO Alireza Tajbakhsh and CFO Carl-Johan Zetterb...
Vimian Group Releases Comprehensive 2025 Annual and Sustainability Report
Mar 19, 2026
Vimian Group AB has published its 2025 Annual Report, detailing its strategy, financial performance and governance structure, alongside extensive sustainability and risk reporting. The report highlights segment overviews, targets and performance m...
Vimian Sets April 29 Date for 2026 AGM and Details Voting Procedures
Mar 19, 2026
Vimian Group AB has called its Annual General Meeting for 29 April 2026 in Stockholm, allowing shareholders to participate either in person or via postal voting. The notice outlines detailed procedures for registration, proxy arrangements, postal ...
Vimian Names Lotta Lundaas to Lead MedTech Unit and Join Group Management
Mar 13, 2026
Vimian Group AB has appointed Lotta Lundaas as Head of MedTech and member of the group management team, effective 13 April 2026, strengthening leadership for its veterinary medical technology operations. Lundaas brings over 15 years of senior expe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.